Novartis AG (SWX:NOVN)
97.63
-0.49 (-0.50%)
Jul 7, 2025, 10:45 AM CET
Novartis AG Employees
Novartis AG had 75,883 employees as of December 31, 2024. The number of employees decreased by 174 or -0.23% compared to the previous year.
Employees
75,883
Change (1Y)
-174
Growth (1Y)
-0.23%
Revenue / Employee
619.98K CHF
Profits / Employee
149.79K CHF
Market Cap
192.24B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 75,883 | -174 | -0.23% |
Dec 31, 2023 | 76,057 | -25,646 | -25.22% |
Dec 31, 2022 | 101,703 | -2,620 | -2.51% |
Dec 31, 2021 | 104,323 | -1,471 | -1.39% |
Dec 31, 2020 | 105,794 | 1,880 | 1.81% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Related Stocks
Company Name | Employees |
---|---|
Roche Holding AG | 103,249 |
Lonza Group AG | 18,944 |
Alcon | 25,599 |
Galderma Group AG | 6,545 |
Sandoz Group AG | 22,049 |
Straumann Holding AG | 11,815 |
Sonova Holding AG | 18,366 |
Ypsomed Holding AG | 2,644 |
Novartis AG News
- 3 days ago - Novartis' Cosentyx Fails Late-Stage Giant Cell Arteritis Trial - Benzinga
- 3 days ago - Novartis fails in late-stage trial for Cosentyx in giant cell arteritis - Seeking Alpha
- 4 days ago - Novartis AG (NVS) Announces Phase III GCAptAIN Study Results for Cosentyx | NVS stock news - GuruFocus
- 4 days ago - Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis ... - GuruFocus
- 4 days ago - Novartis drug Cosentyx fails late-stage trial for artery disease - Reuters
- 4 days ago - Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA) - PRNewsWire
- 4 days ago - Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA) - GlobeNewsWire
- 5 days ago - Notable Insider Move: William Meury Takes Part In Options Exercise At Incyte, Resulting In $0 - Benzinga